Prostate Cancer Radiotherapy: Benefits of Dose

Transcription

Prostate Cancer Radiotherapy: Benefits of Dose
Prostate Cancer Radiotherapy:
Benefits of Dose-Escalation
PCCN: W-W welcomes you to attend our next session with Guest Speaker
Robert Stephens
Rob will speak about his findings of the benefits that dose-escalated
radiotherapy offers men with Prostate Cancer
DATE:
Rob is currently a candidate for a Master of
Tuesday April 28, 2015 Science degree at the University of Waterloo.
He works in Dr. Spafford’s lab studying
TIME:
calcium channel physiology. Formerly, worked
7:00PM – 8:30PM
in the Clinical Trials Department at Grand
River Regional Cancer Centre, and as a student
LOCATION:
volunteer assisting in prostate cancer research
HopeSpring Cancer
with Dr. Gopaul.
Support
16 Andrew St.
This FREE presentation is open to ALL
Kitchener, ON
For Further Information or RSVP - Contact: PCCN:W-W
Answering Service: 226-240-9264
Email: [email protected]
Website: http://pccn-waterloo-wellington.ca
Rob Stephens

Similar documents

Prostate Cancer - Global Drug Forecast and Market Analysis to 2023 for the $8.2 Billion Market

Prostate Cancer - Global Drug Forecast and Market Analysis to 2023 for the $8.2 Billion Market Prostate cancer market was valued at $2.6 billion in 2013 and it is expected to reach $8.3 million, by 2023. It is estimated that the market will grow at a CAGR of 12.4%. This growth will be driven by the label extensions of currently marketed drugs as well as the launch of nine new premium-priced therapies for the treatment of prostate cancer.

More information

Hormone Sensitive Prostate Cancer Market Segments, Opportunity, Growth and Forecast by End-use Industry 2016-2026

Hormone Sensitive Prostate Cancer Market Segments, Opportunity, Growth and Forecast by End-use Industry 2016-2026 Prostate cancer is a general term used for diseased condition in which abnormal cells grow and invade in uncontrolled manner in the prostate. Prostate cancer inhibits production of male sex hormones (i.e. androgens) and ultimately blocks the action of androgen. The androgen is also responsible for the growth of prostate cancer. Androgen binds with the receptors and stimulates the expression of specific genes that would be responsible for prostate cancer. However, androgen suppression hormonal therapies are commonly used for the treatment of this cancer. These therapies acts by reducing the production of androgen by the testicles or by blocking the action of androgen in the body. There is an opportunity for the growth of hormone sensitive prostate cancer owing to the rapidly aging population which is the major cause of prostate cancer.

More information